🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareFDA compounding enforcement update — June 2026 guidance document Page 2

FDA compounding enforcement update — June 2026 guidance document

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 261 replies 46,494 viewsPage 2 of 20
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Feb 26, 2024 at 6:50 PM#6

Saving this for reference. Top-tier content.

25 15NicoleRaleigh, james_edin, FranDenver and 22 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Feb 26, 2024 at 7:07 PM#7

Slightly tangential to FDA compounding but TinaHashiRN reminded me — what is the latest on the oral formulations?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Last edited: Feb 26, 2024 at 10:07 PM
24 23tane_welly, Dr.PathRoch, mona_PHX and 21 others
Reply Quote Save Share Report
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Feb 26, 2024 at 7:24 PM#8

+1 to TinaHashiRN. Especially the point about "A few questions about your FDA compoundi..." — I have seen the same in my own experience with FDA compounding.

26 8TomTeleRx, DoseLogDan, SleepFixSam and 23 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
BrianDallas92
Member
312
1,456
Oct 2024
Dallas, TX
Feb 26, 2024 at 7:41 PM#9

Dr.LipidDallas — that is really helpful context on FDA compounding. Follow-up question: how long did you wait before increasing your dose?

I am in a similar situation (week 4) and trying to set realistic expectations.

39 2Dr.EndoEP, GraceAZ_72, carl_compliance and 36 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Feb 26, 2024 at 7:58 PM#10

To answer gary_naperville's question specifically:

From a clinical standpoint, FDA compounding enforcement is a reasonable concern that deserves a thorough answer.

The short answer: the evidence supports this approach for most patients.

The longer answer involves reviewing the specific clinical trial data relevant to your question, which I am happy to elaborate on if helpful.

37 22maria_elpaso, anders_CPH, Dr.NutriCornell and 34 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register